The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; Roche; Sotio
Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.
 
Amit M. Oza
(OPTIONAL) Uncompensated Relationships - Ozmosis Research
 
Alla Sergeevna Lisyanskaya
Honoraria - AstraZeneca (Inst); INCURON (Inst); MSD (Inst); REGENERON (Inst); Roche (Inst)
Research Funding - AstraZeneca; INCURON; MSD; Regeneron; Roche
 
Alexander A. Fedenko
Consulting or Advisory Role - Amgen; AstraZeneca; Merck Sharp & Dohme; Roche
 
Mikhail Dvorkin
No Relationships to Disclose
 
Andreia Cristina de Melo
Consulting or Advisory Role - Bristol-Myers Squibb; Libbs; Merck Sharp & Dohme
Research Funding - Amgen; Bristol-Myers Squibb; Clovis Oncology; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche
 
Yaroslav V. Shparyk
No Relationships to Disclose
 
Irina Rakhmatullina
No Relationships to Disclose
 
Igor Bondarenko
No Relationships to Disclose
 
Nicoletta Colombo
Honoraria - Amgen; AstraZeneca; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; mersana; MSD Oncology; Novartis; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro
Consulting or Advisory Role - AstraZeneca; BioCad; Clovis Oncology; Eisai; GlaxoSmithKline; Immunogen; mersana; MSD Oncology; Pfizer; Pfizer; PharmaMar; Roche/Genentech; Tesaro
 
Valentyn Svintsitskiy
No Relationships to Disclose
 
David Cibula
No Relationships to Disclose
 
Róbert Póka
No Relationships to Disclose
 
Ana Oaknin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Deciphera; Genmab; GlaxoSmithKline; Immunogen; Mersana; PharmaMar; Roche; Tesaro
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Advaxis (Inst); Aeterna Zentaris (Inst); Amgen (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Clovis Oncology (Inst); Eisai (Inst); Regeneron (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; PharmaMar; Roche
 
Tamar Safra
No Relationships to Disclose
 
Beata Mackowiak-Matejczyk
No Relationships to Disclose
 
Ling Ma
No Relationships to Disclose
 
Karen Retta McLachlan
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Sandra Goble
Employment - Clovis Oncology
Stock and Other Ownership Interests - Clovis Oncology
 
Rebecca Sophie Kristeleit
Honoraria - AstraZeneca; Clovis Oncology; Merck Sharp & Dohme; Roche/Genentech; Tesaro
Consulting or Advisory Role - Basilea; Cerulean Pharma; Clovis Oncology; Roche/Genentech; Sotio
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; Valirx